| Document |
Document Title |
|
WO/2023/272694A1 |
The present invention relates to the field of vitamin C sustained release technology, and specifically relates to a vitamin C and zinc sustained release tablet and a preparation method therefor. Said tablet is made of a tablet-shaped dru...
|
|
WO/2022/269489A1 |
The object of the invention relates to an association of molecular oxygen and hyaluronic acid or its salts for use in the treatment of symptomatology associated with vulvar vestibulitis.
|
|
WO/2022/270112A1 |
[Abstract] Corosolic acid improves insulin resistance and recovers an insulin function that is deteriorated with age. As a result, the insulin sensitivity in an aged person is improved and the metabolism in all cells gets active. [Proble...
|
|
WO/2022/262870A1 |
Provided are a molecular marker combination of ovarian activation, and the use thereof in the preparation of a kit or gene chip for studying ovarian activation or detecting diseases related to abnormal ovarian activation. Also provided i...
|
|
WO/2022/264127A1 |
Described herein are compositions which can be used to alleviate vaginal dryness and vaginal atrophy. The compositions comprise a cannabinoid and a phytoestrogen. Optionally, the composition further comprises a prebiotic agent, preferabl...
|
|
WO/2022/264114A2 |
The invention described herein provides a reactive oxygen species (ROS) responsive linker based on diazaborines (DAB) scaffold. Here we show the ability of diazaborines (DABs) scaffolds to be stable in different biocompatible conditions ...
|
|
WO/2022/265537A1 |
The invention relates to medicine, and more particularly to urology, and can be used for treating erectile dysfunction (ED). The technical result of the invention for which a patent is sought consists in stimulating microcirculation in e...
|
|
WO/2022/257863A1 |
Disclosed are a use of oxytocin or a derivative thereof in the preparation of a preparation for treating or improving lactation insufficiency, and a composition thereof. An improvement method for treating postpartum breast ptosis may be ...
|
|
WO/2022/259195A1 |
The present invention relates to an oral composition comprising at least a citrus fruit extract, preferably a lemon extract from Citrus limon (L.) Osbeck, and at least an Ashwagandha (Withania somnifera (L.) Dunal) extract, and use there...
|
|
WO/2022/260016A1 |
The present invention provides a compound that has a T-type calcium channel blocking effect and that is represented by formula (I) [in the formula, R1, R2, R3, R4, k, l, m, and n are as defined in the description] or a pharmacologically ...
|
|
WO/2022/255568A1 |
The present invention relates to a composition for preventing or treating vaginitus, having Lactobacillus rhamnosus and Lactobacillus acidophilus mixed at a certain ratio, and, by using the composition for preventing or treating vaginiti...
|
|
WO/2022/255284A1 |
The purpose of the present invention is to provide an oral administration agent for pregnant women for increasing the concentration of short-chain fatty acids in the blood of a pregnant woman or the fetus, for imparting resistance to obe...
|
|
WO/2022/252663A1 |
A use of a composition of alcohol and a cooling agent in regulating a sexual function, protecting a cardiovascular and cerebrovascular system, promoting hepatocyte regeneration, fighting against a tumor, and improving the immunity and sl...
|
|
WO/2022/256556A1 |
The invention provides methods of treating and inhibiting mastitis in dairy cows, in need thereof, wherein said method comprises: administering pegbovigrastim to the cow during the late lactation stage and about the dry-off day.
|
|
WO/2022/255978A1 |
The invention relates to a composition used for eliminating genital odors and preventing odor formation.
|
|
WO/2022/251699A1 |
Provided herein are compositions and methods for the treatment of sexual dysfunction and related diseases, disorders, and conditions. An aspect of the present disclosure is a combination comprising at least two compounds independently se...
|
|
WO/2022/251393A1 |
Disclosed herein are intravaginal ring (IVR) devices comprising barriers that may be metal, polymeric or combinations of metal and polymeric. The IVRs are useful for contraception, treating and/or preventing sexually transmitted diseases...
|
|
WO/2022/250108A1 |
The present invention pertains to a therapeutic agent or preventative agent against diseases involving an orexin receptor, particularly an orexin type-2 receptor, the agent containing a novel compound having a urea skeleton, or a pharmac...
|
|
WO/2022/249170A1 |
The invention provides methods for induction of pregnancy in a couple in need thereof wherein the male subject in said couple has been diagnosed as sub-fertile, said method comprising administering systemically to said male subject a pha...
|
|
WO/2022/248269A1 |
A composition for topical application to the oral cavity, for the use in pregnant women to reduce the risk of preterm birth, comprising an ester of vitamin E with a carboxylic acid of formula R-COOH, in which R is an alkyl radical having...
|
|
WO/2022/244815A1 |
Provided are lipid particles in which is encapsulated a nucleic acid, whereby: a vaccine for preventing and/or treating an infection by human papillomavirus type-6 and/or type-11 can be provided; and an E6 antibody and an E7 antibody to ...
|
|
WO/2022/241549A1 |
GHR-106 monoclonal antibody or antigen-binding fragments thereof are provided and used to modulate levels of reproductive hormones in vivo when administered to mammalian subjects. The GHR-106 monoclonal antibody or an antigen-binding fra...
|
|
WO/2022/240983A1 |
The present inventive concept relates to genetic variants, for example, ESR1 rs9340799, and the association of such genetic variants with increased weight gain among contraceptive users, such as contraceptive implant users. Embodiments o...
|
|
WO/2022/237873A1 |
A pharmaceutical composition for treating and/or preventing osteoporosis, the pharmaceutical composition comprising 2-8 parts by weight of Ligustri lucidi fructus, 2-8 parts by weight of Ecliptae herba, 1-5 parts by weight of Spatholobi ...
|
|
WO/2022/238318A1 |
The present invention relates to a method for determining a personalised omega-3 dose to be taken by a pregnant woman to promote a full-term birth.
|
|
WO/2022/239013A1 |
The present invention provides a microbiome microorganisms, microbial consortium, compositions and kits comprising the same and uses thereof.
|
|
WO/2022/235106A1 |
The present invention relates to a crystal form IV of organic acid salts of a compound represented by chemical formula 1, a preparation method thereof, and a pharmaceutical composition comprising same. The crystal form IV of organic acid...
|
|
WO/2022/235693A1 |
The invention provides a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein R1-R6 have any of the values described in the specification, as well as compositions comprising a ...
|
|
WO/2022/235103A1 |
The present invention relates to a sulfate crystal form of a compound represented by formula 1, a method of producing same, and a pharmaceutical composition comprising same. The sulfate crystal form of the compound represented by formula...
|
|
WO/2022/234819A1 |
The present invention provides a non-invasive spawning-inducing oral formulation wherein a new type of GnRHa with a new function of amphiphilicity having a hydrophilic site and a lipophilic site in the GnRHa molecule is created and, as a...
|
|
WO/2022/233312A1 |
The present invention relates to the technical field of oral drugs and health care food for treating and preventing halitosis, hemorrhoids, leukorrhea smell and a combination thereof, and provides an application of a pharmaceutical compo...
|
|
WO/2022/235627A1 |
Methods for non-invasive retrieval of viable (i.e., able to be fertilized) oocytes from the uterus via a combination of unique ovarian stimulation and uterine lavage technology. These methods may eliminate the need for an invasive surgic...
|
|
WO/2022/235104A1 |
The present invention relates to crystalline form V of a compound represented by chemical formula 1, a method for preparing same, and a pharmaceutical composition comprising same. Crystalline form V of the compound represented by chemica...
|
|
WO/2022/235107A1 |
The present invention relates to a co-crystal of a compound represented by chemical formula 1 and vanillin, a method for preparing same, and a pharmaceutical composition comprising same. The co-crystal of the compound represented by chem...
|
|
WO/2022/235105A1 |
The present invention relates to a crystal form VII of a compound represented by chemical formula 1, a method for preparing same, and a pharmaceutical composition comprising same. The crystal form VII of the compound represented by chemi...
|
|
WO/2022/229965A1 |
The present disclosure provides compositions and methods for modulating various mammary' disorders and conditions. The disclosure further provides a therapeutic combination of a composition of at least one casein protein or casein-derive...
|
|
WO/2022/227814A1 |
The present invention belongs to the technical field of traditional Chinese medicine (TCM), and specifically disclosed are a TCM composition for treating infertility, a preparation method therefor, and an application thereof. The TCM com...
|
|
WO/2022/229320A1 |
The present invention relates to compositions comprising gingeroids or ginger oleoresin; in particular, compositions comprising gingeroids or ginger oleoresin that are highly water soluble and have an increased bioavailability. The prese...
|
|
WO/2022/228317A1 |
A class of piperazine derivatives and an application thereof, specifically a compound represented by formula (III) or a pharmaceutically acceptable salt thereof.
|
|
WO/2022/228413A1 |
Disclosed in the present invention are an RIPK1 inhibitor for inhibiting programmed cell death and a preparation method therefor. The RIPK1 inhibitor of the present invention is as represented by general formula I, wherein X, Y, Z, L, R1...
|
|
WO/2022/225986A1 |
The present invention provides methods of female contraception, the methods comprising administering an effective amount of a combination of a progesterone receptor agonist and a cyclooxygenase-2 inhibitor in each of two doses, the first...
|
|
WO/2022/218487A1 |
The disclosure relates to a vaginal contraceptive composition comprising one or more active ingredients and at least one formulation compound selected from a physiological acceptable gelling agent or a physiological acceptable carrier, w...
|
|
WO/2022/174074A9 |
Provided are methods of modulating gene expression levels in an individual identified as having endometriosis. The methods comprise administering to the individual identified as having endometriosis a drug described herein in an amount e...
|
|
WO/2022/220458A1 |
The present invention relates to a composition including an Aurantii Fructus Immaturus extract as an active ingredient for prevention or treatment of male climacteric symptoms. A composition according to an aspect has effects of increasi...
|
|
WO/2022/215704A1 |
The present invention pertains to a conjugate body represented by Lg-Lk-NCA wherein Lk is a linker moiety, NCA is a nucleic acid moiety and Lg is a group represented by one of the formulae.
|
|
WO/2022/206968A1 |
Crystalline forms of a GnRH receptor antagonist and a preparation method therefor. Specifically, provided are the crystal forms E, F, G, K and O of a compound as represented by formula (I) and a preparation method therefor.
|
|
WO/2022/206838A1 |
A polypeptide comprising two or three VEGF binding domains; and a domain that binds to an angiopoietin, and a gene therapy for delivering such a polypeptide.
|
|
WO/2022/212529A1 |
A transdermal system for providing estrogen to a patient in need thereof is provided. The transdermal system comprises a backing, and a matrix contacting the backing, the matrix configured to release about 4 mcg per day to about 36 mcg p...
|
|
WO/2022/207902A1 |
The present invention relates to a composition comprising between 35 and 55% by weight of a polymer matrix comprising a thermoplastic polymer having a Shore A hardness of between 20 and 100 as measured by a Type A durometer according to ...
|
|
WO/2022/204904A1 |
Provided is the use of a human amniotic epithelial cell (hAECS) in preparation of a drug for treating and/or alleviating intrauterine adhesion diseases.
|
